Exenatide Extended-Release Suspension for Injection Shortage
Last Updated: February 10, 2025
Status: Resolved
Products Affected - Description
-
- Bydureon BCise subcutaneous suspension for injection, AstraZeneca, 2 mg, 0.85 mL auto-injector, 4 count, NDC 00310-6540-04 - discontinued
- Bydureon Pen subcutaneous suspension for injection, AstraZeneca, 2 mg, 0.65 mL pen injector, 4 count, NDC 00310-6530-04 - discontinued
Reason for the Shortage
-
- AstraZeneca has discontinued Bydureon BCise.
- AstraZeneca has discontinued Bydureon Pens.
Estimated Resupply Dates
-
- AstaZeneca has discontinued all Bydureon products.
Updated
Updated February 10, 2025 by Michelle Wheeler, PharmD, Drug Information Specialist. Created March 20, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. © 2025, Drug Information Service, University of Utah, Salt Lake City, UT.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.